why choose us

Course: Optimizing Outcomes in Relapsed/Refractory NHL: Bringing CAR T-Cell Therapies to Rural and Underserved Communities

CME Credits: 0.00

Released: 2026-01-15

The advent of chimeric antigen receptor (CAR) T-cell therapies has revolutionized management of relapsed/refractory non-Hodgkin lymphomas (R/R NHLs). Early identification of potentially eligible candidates, ideally at the earliest indications of treatment failure, can help mitigate logistical issues and maximize the likelihood of patients receiving therapy expeditiously, leading to optimal outcomes. However, community oncologists who care for patients with NHL in rural and underserved communities face several challenges that make it difficult to integrate complex therapies like CAR T-cell therapy into treatment plans. This on-demand CME/CE activity will review the latest clinical evidence surrounding CAR T-cell therapy for individuals with R/R NHL and strategies to individualize treatment decision-making. Expert faculty will also discuss interprofessional and patient-centric strategies to improve timely referral, adverse event management, and post-infusion care for patients with NHL in rural and underserved areas. This enduring activity is a recorded session from Oncology Congress that took place on October 25, 2025.


Upon completion of this activity, participants should be better able to:


View Full Course